Inhibition of gene expression of organic cation/carnitine transporter and antioxidant enzymes in oxazaphosphorines-induced acute cardiomyopathic rat models

Oxidative Medicine and Cellular Longevity

Volumn , Issue , 2012, Pages

  Sayed Ahmed, Mohamed M ^a   Aldelemy, Meshan Lafi ^a   Hafez, Mohamed M ^a   Al Shabanah, Othman A ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT ENZYME; CARDIAC TISSUES; CARDIOTOXICITY; CARNITINE; CONTROL VALUES; IFOSFAMIDE; KIDNEY TISSUES; L-CARNITINE; ORGANIC CATIONS; PROTEIN EXPRESSIONS; RAT MODEL; THERAPEUTIC DOSE; TREATMENT GROUP;

ENZYME INHIBITION; HEART; HISTOLOGY; PROTEINS; TISSUE;

GENE EXPRESSION;

ACYLCARNITINE; CARNITINE; CARRIER PROTEIN; CYCLOPHOSPHAMIDE; IFOSFAMIDE; MESSENGER RNA; OCTN2 PROTEIN; UNCLASSIFIED DRUG; CREATINE KINASE; LACTATE DEHYDROGENASE; ORGANIC CATION TRANSPORTER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; CARDIOTOXICITY; CONTROLLED STUDY; FATTY ACID BLOOD LEVEL; KIDNEY PARENCHYMA; KIDNEY PROXIMAL TUBULE; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; SUPPLEMENTATION; URINARY EXCRETION; ANIMAL; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENE EXPRESSION; GENETICS; METABOLISM; WISTAR RAT;

ANIMALS; CARDIOMYOPATHIES; CARNITINE; CREATINE KINASE; CYCLOPHOSPHAMIDE; GENE EXPRESSION; IFOSFAMIDE; KIDNEY TUBULES, PROXIMAL; L-LACTATE DEHYDROGENASE; MALE; ORGANIC CATION TRANSPORT PROTEINS; RATS; RATS, WISTAR;

EID: 84862287779     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2012/452902     Document Type: Article

References (65)

1. Shore S., Review of the nitrogen mustards Hahnemann Monthly 1947 82 11 461 470
2. Baumann F., Preiss R., Cyclophosphamide and related anticancer drugs Journal of Chromatography B 2001 764 1-2 173 192 (Pubitemid 33044665)
3. Shanholtz C., Acute life-threatening toxicity of cancer treatment Critical Care Clinics 2001 17 3 483 502 (Pubitemid 32777560)
4. Mythili Y., Sudharsan P. T., Selvakumar E., Varalakshmi P., Protective effect of DL- -lipoic acid on cyclophosphamide induced oxidative cardiac injury Chemico-Biological Interactions 2004 151 1 13 19 (Pubitemid 39647933)
5. Morandi P., Ruffini P. A., Benvenuto G. M., Raimondi R., Fosser V., Cardiac toxicity of high-dose chemotherapy Bone Marrow Transplantation 2005 35 4 323 334 (Pubitemid 40309476)
6. Katayama M., Imai Y., Hashimoto H., Kurata M., Nagai K., Tamita K., Morioka S., Furukawa Y., Fulminant fatal cardiotoxicity following cyclophosphamide therapy Journal of Cardiology 2009 54 2 330 334
7. Todorova V., Vanderpool D., Blossom S., Nwokedi E., Hennings L., Mrak R., Klimberg V. S., Oral glutamine protects against cyclophosphamide-induced cardiotoxicity in experimental rats through increase of cardiac glutathione Nutrition 2009 25 7-8 812 817
8. Fatani A. G., Darweesh A. Q., Rizwan L., Aleisa A. M., Al-Shabanah O. A., Sayed-Ahmed M. M., Carnitine deficiency aggravates cyclophosphamide-induced cardiotoxicity in rats Chemotherapy 2010 56 1 71 81
9. Mills B. A., Roberts R. W., Cyclophosphamide-induced cardiomyopathy. A report of two cases and review of the English literature Cancer 1979 43 6 2223 2226 (Pubitemid 9246391)
10. Goldberg M. A., Antin J. H., Guinan E. C., Rappeport J. M., Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor Blood 1986 86 5 1114 1118 (Pubitemid 17186389)
11. Gottdiener J. S., Appelbaum F. R., Ferrans V. J., Cardiotoxicity associated with high-dose cyclophosphamide therapy Archives of Internal Medicine 1981 141 6 758 763 (Pubitemid 11120879)
12. Steinherz L. J., Steinherz P. G., Mangiacasale D., Cardiac changes with cyclophosphamide Medical and Pediatric Oncology 1981 9 5 417 422 (Pubitemid 12245874)
13. Nicolini A., Mancini P. A., Ferrari P., Anselmi L., Tartarelli G., Bonazzi V., Carpi A., Giardino R., Oral low-dose cyclophosphamide in metastatic hormone refractory prostate cancer (MHRPC) Biomedicine and Pharmacotherapy 2004 58 8 447 450 (Pubitemid 39349493)
14. Kandylis K., Vassilomanolakis M., Tsoussis S., Efremidis A. P., Ifosfamide cardiotoxicity in humans Cancer Chemotherapy and Pharmacology 1989 24 6 395 396 (Pubitemid 19239321)
15. Quezado Z. M. N., Wilson W. H., Cunnion R. E., Parker M. M., Reda D., Bryant G., Ognibene F. P., High-dose ifosfamide is associated with severe, reversible cardiac dysfunction Annals of Internal Medicine 1993 118 1 31 36 (Pubitemid 23007969)
16. Buckner C., Rudolph R., Fefer A., High-dose cyclophosphamide therapy for malignant disease. Toxicity, tumor response, and the effects of stored autologous marrow Cancer 1972 29 357 365
17. Nagi M. N., Al-Shabanah O. A., Hafez M. M., Sayed-Ahmed M. M., Thymoquinone supplementation attenuates cyclophosphamide-induced cardiotoxicity in rats Journal of Biochemical and Molecular Toxicology 2011 25 3 135 142
18. Sehirli O., Sakarcan A., Velioglu-Ogunc A., Resveratrol improves ifosfamide-induced Fanconi syndrome in rats Toxicology and Applied Pharmacology 2007 222 1 33 41 (Pubitemid 46962655)
19. Sayed-Ahmed M. M., Darweesh A. Q., Fatani A. J., Carnitine deficiency and oxidative stress provoke cardiotoxicity in an ifosfamide-induced Fanconi Syndrome rat model Oxidative Medicine and Cellular Longevity 2010 3 4 266 274
20. Bremer J., Carnitine. Metabolism and functions Physiological Reviews 1983 63 4 1420 1480 (Pubitemid 14213918)
21. Kunau W. H., Dommes V., Schulz H., -oxidation of fatty acids in mitochondria, peroxisomes, and bacteria: a century of continued progress Progress in Lipid Research 1995 34 4 267 342
22. Vaz F. M., Wanders R. J. A., Carnitine biosynthesis in mammals Biochemical Journal 2002 361 3 417 429 (Pubitemid 34177810)
23. Tamai I., Ohashi R., Nezu J. I., Yabuuchi H., Oku A., Shimane M., Sai Y., Tsujit A., Molecular and functional identification of sodium ion-dependent, high affinity human carnitine transporter OCTN2 Journal of Biological Chemistry 1998 273 32 20378 20382 (Pubitemid 28377603)
24. Maeda T., Wakasawa T., Funabashi M., Fukushi A., Fujita M., Motojima K., Tamai I., Regulation of Octn2 transporter (SLC22A5) by peroxisome proliferator activated receptor alpha Biological and Pharmaceutical Bulletin 2008 31 6 1230 1236 (Pubitemid 351871185)
25. Visarius T. M., Bhler H., Kpfer A., Cerny T., Lauterburg B. H., Thiodiglycolic acid is excreted by humans receiving ifosfamide and inhibits mitochondrial function in rats Drug Metabolism and Disposition 1998 26 3 193 196 (Pubitemid 28182392)
26. Marthaler N. P., Visarius T., Kpfer A., Lauterburg B. H., Increased urinary losses of carnitine during ifosfamide chemotherapy Cancer Chemotherapy and Pharmacology 1999 44 2 170 172 (Pubitemid 29297065)
27. Visarius T. M., Stucki J. W., Lauterburg B. H., Inhibition and stimulation of long-chain fatty acid oxidation by chloroacetaldehyde and methylene blue in rats Journal of Pharmacology and Experimental Therapeutics 1999 289 2 820 824 (Pubitemid 29191237)
28. Graziano F., Bisonni R., Catalano V., Silva R., Rovidati S., Mencarini E., Ferraro B., Canestrari F., Baldelli A. M., De Gaetano A., Giordani P., Testa E., Lai V., Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients British Journal of Cancer 2002 86 12 1854 1857
29. Sayed-Ahmed M. M., Progression of cyclophosphamide-induced acute renal metabolic damage in carnitine-depleted rat model Clinical and Experimental Nephrology 2010 14 5 418 426
30. Sayed-Ahmed M. M., L-Carnitine attenuates ifosfamide-induced carnitine deficiency and decreased intramitochondrial CoA-SH in rat kidney tissues Journal of Nephrology 2011 24 4 490 498
31. Ciarimboli G., Holle S. K., Vollenbrcker B., Hagos Y., Reuter S., Burckhardt G., Bierer S., Herrmann E., Pavenstdt H., Rossi R., Kleta R., Schlatter E., New clues for nephrotoxicity induced by ifosfamide: preferential renal uptake via the human organic cation transporter 2 Molecular Pharmaceutics 2011 8 1 270 279
32. Chomczynski P., A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples BioTechniques 1993 15 3 532 537 (Pubitemid 23270488)
33. Buhl S. N., Jackson K. Y., Optimal conditions and comparison of lactate dehydrogenase catalysis of the lactate to pyruvate and pyruvate to lactate reactions in human serum at 25, 30, and 37C Clinical Chemistry 1978 24 5 828 831 (Pubitemid 8338630)
34. Wu A. H. B., Bowers G. N. Jr., Evaluation and comparison of immunoinhibition and immunoprecipitation methods for differentiating MB from BB and macro forms of creatine kinase isoenzymes in patients and healthy individuals Clinical Chemistry 1982 28 10 2017 2021 (Pubitemid 12034043)
35. Prieto J. A., Andrade F., Aldmiz-Echevarra L., Sanjurjo P., Determination of free and total carnitine in plasma by an enzymatic reaction and spectrophotometric quantitation spectrophotometric determination of carnitine Clinical Biochemistry 2006 39 10 1022 1027 (Pubitemid 44442155)
36. Heuberger W., Berardi S., Jacky E., Pey P., Krhenbhl S., Increased urinary excretion of carnitine in patients treated with cisplatin European Journal of Clinical Pharmacology 1998 54 7 503 508 (Pubitemid 28487369)
37. Mancinelli A., D'Iddio S., Bisonni R., Graziano F., Lippe P., Calvani M., Urinary excretion of l-carnitine and its short-chain acetyl-l-carnitine in patients undergoing carboplatin treatment Cancer Chemotherapy and Pharmacology 2007 60 1 19 26 (Pubitemid 46643713)
38. Haschke M., Vitins T., Lde S., Todesco L., Novakova K., Herrmann R., Krhenbhl S., Urinary excretion of carnitine as a marker of proximal tubular damage associated with platin-based antineoplastic drugs Nephrology Dialysis Transplantation 2010 25 2 426 433
39. Ramsay R. R., Gandour R. D., van der Leij F. R., Molecular enzymology of carnitine transfer and transport Biochimica et Biophysica Acta 2001 1546 1 21 43 (Pubitemid 32217800)
40. Lamhonwah A. M., Skaug J., Scherer S. W., Tein I., A third human carnitine/organic cation transporter (OCTN3) as a candidate for the 5q31 Crohn's disease locus (IBD5) Biochemical and Biophysical Research Communications 2003 301 1 98 101 (Pubitemid 36268853)
41. Xuan W., Lamhonwah A. M., Librach C., Jarvi K., Tein I., Characterization of organic cation/carnitine transporter family in human sperm Biochemical and Biophysical Research Communications 2003 306 1 121 128 (Pubitemid 36629414)
42. Abraham P., Rabi S., Nitrosative stress, protein tyrosine nitration, PARP activation and NAD depletion in the kidneys of rats after single dose of cyclophosphamide Clinical and Experimental Nephrology 2009 13 4 281 287
43. Ganapathy M. E., Huang W., Rajan D. P., Carter A. L., Sugawara M., Iseki K., Leibach F. H., Ganapathy V., -Lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter Journal of Biological Chemistry 2000 275 3 1699 1707 (Pubitemid 30060789)
44. Wagner C. A., Lkewille U., Kaltenbach S., Moschen I., Brer A., Risler T., Brer S., Lang F., Functional and pharmacological characterization of human Na+-carnitine cotransporter hOCTN2 American Journal of Physiology 2000 279 3 F584 F591
45. Sayed-Ahmed M. M., Al-Shabanah O. A., Hafez M. M., Aleisa A. M., Al-Rejaie S. S., Inhibition of gene expression of heart fatty acid binding protein and organic cation/carnitine transporter in doxorubicin cardiomyopathic rat model European Journal of Pharmacology 2010 640 13 143 149
46. Asiri Y. A., Probucol attenuates cyclophosphamideinduced oxidative apoptosis, p53 and Bax signal expression in rat cardiac tissues Oxidative Medicine and Cellular Longevity 2010 3 5 308 316
47. Fritz I. B., Arrigoni-Martelli E., Sites of action of carnitine and its derivatives on the cardiovascular system: interactions with membranes Trends in Pharmacological Sciences 1993 14 10 355 360 (Pubitemid 23308758)
48. Sayed-Ahmed M. M., Shouman S. A., Rezk B. M., Khalifa M. H., Osman A. M. M., El-Merzabani M. M., Propionyl-L-carnitine as potential protective agent against adriamycin-induced impairment of fatty acid beta-oxidation in isolated heart mitochondria Pharmacological Research 2000 41 2 143 150 (Pubitemid 30670330)
49. Sayed-Ahmed M. M., Khattab M. M., Gad M. Z., Mostafa N., L-carnitine prevents the progression of atherosclerotic lesions in hypercholesterolaemic rabbits Pharmacological Research 2001 44 3 235 242 (Pubitemid 32889467)
50. Al-Majed A. A., Sayed-Ahmed M. M., Al-Omar F. A., Al-Yahya A. A., Aleisa A. M., Al-Shabanah O. A., Carnitine esters prevent oxidative stress damage and energy depletion following transient forebrain ischaemia in the rat hippocampus Clinical and Experimental Pharmacology and Physiology 2006 33 8 725 733 (Pubitemid 44060765)
51. Augustyniak A., Skrzydlewska E., The influence of L-carnitine suplementation on the antioxidative abilities of serum and the central nervous system of ethanol-induced rats Metabolic Brain Disease 2010 25 4 381 389
52. Bodea F., Bocea A., Decea N., L-carnitine decreases oxidative stress induced by experimental hypobaric hypoxia Pediatric Endocrinology, Diabetes, and Metabolism 2010 16 2 78 81
53. Liu J., The effects and mechanisms of mitochondrial nutrient -lipoic acid on improving age-associated mitochondrial and cognitive dysfunction: an overview Neurochemical Research 2008 33 1 194 203 (Pubitemid 350242787)
54. Chen H. H., Sue Y. M., Chen C. H., Hsu Y. H., Hou C. C., Cheng C. Y., Lin S. L., Tsai W. L., Chen T. W., Chen T. H., Peroxisome proliferator-activated receptor alpha plays a crucial role in l-carnitine anti-apoptosis effect in renal tubular cells Nephrology Dialysis Transplantation 2009 24 10 3042 3049
55. Ozsoy S. Y., Ozsoy B., Ozyildiz Z., Aytekin I., Protective effect of L-carnitine on experimental lead toxicity in rats: a clinical, histopathological and immunohistochemical study Biotechnic and Histochemistry 2010 86 6 436 443
56. Goa K. L., Brogden R. N., l-Carnitine: a preliminary review of its pharmacokinetics, and its therapeutic use in ischaemic cardiac disease and primary and secondary carnitine deficiencies in relationship to its role in fatty acid metabolism Drugs 1987 34 1 1 24 (Pubitemid 17092320)
57. Luo X., Reichetzer B., Trines J., Benson L. N., Lehotay D. C., L-carnitine attenuates doxorubicin-induced lipid peroxidation in rats Free Radical Biology and Medicine 1999 26 9-10 1158 1165 (Pubitemid 29262701)
58. Campos Y., Huertas R., Lorenzo G., Bautista J., Gutierrez E., Aparicio M., Alesso L., Arenas J., Plasma carnitine insufficiency and effectiveness of L-carnitine therapy in patients with mitochondrial myopathy Muscle and Nerve 1993 16 2 150 153 (Pubitemid 23030999)
59. Bohles H., Evangeliou A., Bervoets K., Eckert I., Sewell A., Carnitine esters in metabolic disease European Journal of Pediatrics 1994 153 1 S57 S61
60. Winter S. C., Zorn E. M., Vance W. H., Carnitine deficiency Lancet 1990 335 8695 981 982
61. Neely J. R., Morgan H. E., Relationship between carbohydrate and lipid metabolism and the energy balance of heart muscle Annual Review of Physiology 1974 36 413 459
62. Koc A., Duru M., Ciralik H., Akcan R., Sogut S., Protective agent, erdosteine, against cisplatin-induced hepatic oxidant injury in rats Molecular and Cellular Biochemistry 2005 278 1-2 79 84 (Pubitemid 41418922)
63. Tiersten A., Wo J., Jacobson C., Weitzman A., Horwich T., Hesdorffer C., Savage D., Troxel A., Cardiac toxicity observed in association with high-dose cyclophosphamide-based chemotherapy for metastatic breast cancer Breast 2004 13 4 341 346 (Pubitemid 39172737)
64. Selvakumar E., Prahalathan C., Sudharsan P. T., Varalakshmi P., Protective effect of lipoic acid on cyclophosphamide-induced testicular toxicity Clinica Chimica Acta 2006 367 1-2 114 119
65. Kumar S. A., Sudhahar V., Varalakshmi P., Protective role of eicosapentaenoate-lipoate (EPA-LA) derivative in combating oxidative hepatocellular injury in hypercholesterolemic atherogenesis Atherosclerosis 2006 189 1 115 122 (Pubitemid 44441286)